However, a number of previous reports disagree on whether TERT promoter mutations are responsible for elevated TERT expression or low patient survival rate in a variety of cancers, including, but not limited to, cutaneous melanoma [13, 14], thyroid cancer [15], bladder cancer [16–18], and HCC [19, 20]. This evidence concerns the gene TERT and hepatocellular carcinoma.